The mutations of macrophage colony-stimulating factor 1 receptor (FMS)-like tyrosine kinase-3 (FLT3) occur in about one third of adult patients with AML, and determine the poor prognosis of these patients. Recently, some physicians had tested tyrosine kinase inhibitor, sorafenib, for FLT3 þ AML patients relapsed after SCT. [1] [2] [3] [4] [5] Sorafenib is a multikinase inhibitor active against tyrosine kinase receptors such as vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR3, PDGF receptor, FLT3 and c-kit. 6, 7 It has also been reported that sorafenib induces apoptosis in human leukemia cells through the inhibition and downregulation of myeloid cell leukemia-1, a member of the Bcl-2 family. 8 Different adverse events were seen during sorafenib administration: dermatologic manifestations from rash to hand-foot syndrome, diarrhea, nausea, anorexia, oral mucositis and vomiting, and constitutional effects like fatigue, weight loss and hypertension. 9 In leukemic patients, sorafenib induced more frequently leucopenia and thrombocytopenia needing platelet transfusions.
Recently, Alexandrescu et al. 10 described the occurrence of erythrocytosis in 5 of 21 patients receiving tyrosine kinase inhibitors for metastatic cancers.
We reported the case of a 21-year-old man with a diagnosis of FLT3 þ AML, treated with a high dose of cytarabine and DNR, and submitted to allo-SCT from his HLA identical sister after conditioning with BU 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg) and CY 60 mg/kg once daily i.v. on days À3 and À2 (total dose 120 mg/kg). GVHD prophylaxis consisted of CsA and a short course of MTX. His post-transplant course was uneventful. Chimerism by PCR-based analysis of polymorphic STR markers showed a donor pattern of 99% from BM samples obtained on days þ 15, þ 30 and þ 60, and 100% on day þ 90, respectively. CsA was tapered until 5 months after allo-SCT, when the patient was admitted for leukemia relapse. He received a conditioning regimen with FLA-IDA (Ara-C 2 g/m 2 by continuous i.v. infusion over 24 h for 4 consecutive days, fludarabine 30 mg/m 2 once daily i.v. on days 1-4, idarubicin 10 mg/m 2 once daily i.v. on days 2 and 3) and a second allo-SCT from the same donor. No GVHD prophylaxis was adopted in order to elicit a GVL effect and, a single dose of donor lymphocytes (1 Â 10 6 /kg) was administered at day þ 30 post transplant. CR was achieved and the patient presented acute GVHD III grade of liver and skin treated with four sessions of extracorporeal photopheresis, steroids and mycophenolate mofetil. Unfortunately, the patient presented a further BM and extramedullary (skin) relapse 8 months after the second allo-SCT. Ara-C 100 mg/m 2 once daily i.v. for 8 days and gemtuzumab ozogamycin 5 mg/m 2 on day 9 were administered, and radiotherapy for extramedullary skin lesions refractory to chemotherapy was then applied. Twelve months after the second allo-SCT, the patient developed a painful jaw swelling that was related to muscular localization of leukemia. At computerized tomography a widespread swelling of muscles in left masticatory region that substituted completely for contiguous adipose tissue was detected together with several adjacent lymphadenopathies and thickening of Waldeyer's ring. Radiotherapy on the involved field was administered. A month after, the patient relapsed newly in BM and progressed at extramedullary sites (skin and soft tissue). Compassionate use of sorafenib was offered after informed consent and institutional review board approval. An unrelated donor search was started and sorafenib 400 mg b.i.d. was administered. The patient entered CR in the BM and obtained complete resolution of extramedullary lesions quickly (30 days) after the introduction of sorafenib. Complete molecular remission and full donor chimerism was reestablished and the patient is maintaining CR for 15 months on sorafenib. Grade II skin rash and grade II liver toxicity according to the National Cancer Institute criteria were observed, which resolved after temporary discontinuation and dose reduction of sorafenib. The patient was monitored weekly for hematological and clinical parameters during treatment.
Erythrocytosis occurred rapidly, reaching 53.8% with hemoglobin level of 18.2 g/dL after 2 weeks of sorafenib administration. Temporary drug discontinuation for progressive erythrocytosis and skin rash were accompanied by regression of erythrocytosis. Hence, sorafenib was reintroduced at 100 mg/day, then raised at 200 mg b.i.d. after a few weeks. After 7 months of therapy, the patient presented extensive chronic skin GVHD with depigmentation and hyperkeratotic lesions, and sorafenib was reduced to 200 mg/day. Gradually, we observed a new recurrence of erythrocytosis (hematocrit (Hct)49.7%, Hb 16.1 g/dL) without any known causes such as volume contraction or hypoxia. The EPO level was normal (11.4 mU/mL, normal range 2-19.5), and JAK2V617F mutation was negative. Hence, sorafenib was reduced at 100 mg/day with benefit (Figure 1) . This is the first report on erythrocytosis occurring in an AML patient during sorafenib administration. The occurrence of increased Hb/Hct temporally related with sorafenib treatment suggests that the possible cause is the tyrosine kinase inhibitor itself. As the EPO level was normal and JAK3V617F was negative in our patient, erythrocytosis may have been induced by a different mechanism. As suggested by Alexandrescu et al., 10 we thought that the vascular endothelial growth factor blockage by sorafenib could induce an elevation of red cell mass by means of hypoxia-induced stimulus. Erythrocytosis in our patient could be the result of stimulation of donor erythropoiesis by sorafenib. This effect has not been described before in patients with AML, probably, because the majority of these patients have not been treated with sorafenib after allo-SCT. We suppose that the hyperstimulation of donor erythropoiesis is similar to that observed in patients with solid cancer and normal hematopoiesis.
The real mechanism of erythrocytosis induced by sorafenib was unknown.
In conclusion, we report the first case of reversible erythrocytosis, which occurred in the patients who had undergone allogeneic transplantation for recurrent/refractory AML and were treated successfully with the tyrosine kinase inhibitor, sorafenib. 
